Nautilus Biotech of France and Microbix Biosystems of Canada announce a distribution agreement for academic applications of NautCell, a high-producer cell-line for recombinant Adeno-associated vectors
NautCell has been developed by Nautilus using its proprietary high- throughput Platform Biomics technology for cell-directed evolution, after more than 40,000 individual recombinant Adeno-associated vectors (rAAV) viral infections with rAAV produced by cell clones obtained from the Microbix 293 HEK cell line.
NautCell displays a stable 1-2 logs higher productivity for rAAV compared to the parental 293 HEK cells.
NautCell is a powerful and reliable tool to meet the rapidly growing rAAV manufacturing scale and needs for applications in the fields of gene therapy and vaccines.
"Nautilus's Platform Biomics technology is an excellent tool for optimising and screening a variety of cell lines as demonstrated by their creation of NautCell.
We are pleased to have the opportunity to provide another technology to our customers that will help bring new therapies to market," stated William J Gastle, president and CEO of Microbix.
Nautilus Biotech is is involved in areas it describes as directed evolution, functional genomics target characterisation, and cell-line engineering for complex systems. Microbix Biosystems specialises in developing and manufacturing tissue culture-derived biologicals for biotherapeutic drugs and vaccines.
It makes reagents for building diagnostic products and tools used in biotechnology research.
The company has expertise in advanced culture, purification and process validation technologies.
